At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 53 enrolled
Drug / intervention
HB-adMSCs +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled, Clinical Trial to Assess Efficacy and Safety of Allogeneic HB-adMSCs to Provide Immune Support Against COVID-19.
In Brief
A Phase 2 clinical trial evaluating HB-adMSCs and Placebos for COVID-19. Completed, enrolled 53 participants across 1 site.
Detailed Summary
Hope Biosciences is conducting a research study of an investigational product called allogeneic adipose-derived mesenchymal stem cells (abbreviated as HB-adMSCs) to provide immune support against COVID-19. The study purpose is to evaluate the safety and efficacy of five IV infusions of HB-adMSCs in subjects with no signs of COVID-19.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCOVID-19
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedApr 2020
Enrollment StartMay 2020
Primary CompletionMay 2021
TodayJul 2026
First PostedApr 16, 2020
Enrollment StartMay 14, 2020
Primary CompletionMay 12, 2021
TodayJul 2, 2026
Enrollment to primary: 12 monthsPosted 6.2 years ago
Interventions
HB-adMSCsbiological
Hope Biosciences allogeneic adipose-derived mesenchymal stem cells
Placebosother
Saline